DNAprint Genomics (DNAG)

[dgplexus]

DNAPrint Genomics very clearly is a part of the Personalized Medicine space, as even the most casual observer can see. Don't be confused by the various terminology... "personalized medicine," "pharmacogenomics," "theranostics," etc. This is about personalized medicine, by whatever name it's called. It's not uncommon for an emerging field or industry to have multiple descriptive names, in its formative stages. "Personalized Medicine" appears to be the leading term at this moment, largely because the Obama administration refers to it as that.

http://www.dnaprint.com/welcome/corporate/

Relevant excerpt:

Pharmacogenomics Market - The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition. We at DNAPrint® believe that as doctors and health care providers have been reporting for thousands of years; that different peoples from different countries have variable responses to medications is reason enough for us to explore this realm of medicine. We hope to be able to help predict whether a woman taking a chemotherapy agent for a cancer will respond favorably to a drug. We also will apply our technology to our own therapeutics, such as PT-401 a ‘super EPO’. This will help improve the efficacy of the drug therapy going into clinical evaluation as well as helping to improve and maintain patient response efficacy after the drug is approved. Pharmaceutical and pharmaceutical diagnostics are important cornerstones for our future value to our shareholders. We believe individualized medicine, while still some years away, will be here to stay, especially now that the U.S. FDA has written about pharmacogenomics. view PDF
http://www.dnaprint.com/welcome/pdf/2003d-0497-gdl0002.pdf